Arch Venture Management’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Arch Venture Management’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,940,503	Closed	-$1.32M	–	9
2022 Q4	$1.32M	Hold	2,940,503	–	–	0.34%	8
2022 Q3	$1.43M	Hold	2,940,503	–	–	0.18%	9
2022 Q2	$1.47M	Hold	2,940,503	–	–	0.18%	8
2022 Q1	$1.79M	Buy	+2,940,503	New	+$1.54M	0.26%	7

Other funds holding MTCR

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Arch Venture Management's MTCR Position: Q1 2023 in Review

Arch Venture Management sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 2,940,503 shares — an estimated $1.32M sold.

Arch Venture Management first reported a position in MTCR in Q1 2022 and held it in 4 quarters. The position peaked at $1.79M in Q1 2022. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

Arch Venture Management reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Arch Venture Management sold 2,940,503 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $1.32M.
Arch Venture Management first reported a position in Metacrine, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Arch Venture Management's Metacrine, Inc. Common Stock position peaked at $1.79M in Q1 2022.
5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Arch Venture Management's 13F filing for Q1 2023, filed 15 May 2023.